

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Purified anti-human CD28

RRID:AB_314303

Type: Antibody

Proper Citation

BioLegend Cat# 302901, RRID:AB_314303

Antibody Information

URL: http://antibodyregistry.org/AB_314303

Proper Citation: BioLegend Cat# 302901, RRID:AB_314303

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F, Costim, FA

Antibody Name: Purified anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_314303

Vendor: BioLegend

Catalog Number: 302901

Alternative Catalog Numbers: 302902

Record Creation Time: 20250820T014115+0000

Record Last Update: 20250820T113528+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD28.

No alerts have been found for Purified anti-human CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Kempen L, et al. (2026) Gammaherpesvirus infection impairs lung fibrosis resolution through PD-L1+ fibroblasts and PD-1+ CD8+ T cell interaction. *Mucosal immunology*, 100388.

Lobel L, et al. (2026) Dietary sulfur amino acids enhance anti-tumor immunity in colon cancer via an NKT cell-XCL1-cDC1 circuit. *Immunity*, 59(6), 1708.

Moro A, et al. (2025) Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming. *iScience*, 28(6), 112553.

Lv J, et al. (2025) Mechanical signaling via $\alpha 2$ integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells. *Immunity*, 58(9), 2289.

Sun J, et al. (2025) Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. *Cancer immunology research*, 13(3), 400.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. *Cell reports. Medicine*, 6(12), 102510.

Kögl T, et al. (2024) Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect. *The Journal of experimental medicine*, 221(7).

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. *Immunity*, 57(9), 2232.

Teijeira A, et al. (2024) Low-Dose Ionizing γ -Radiation Elicits the Extrusion of Neutrophil Extracellular Traps. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4131.

Jackson JW, et al. (2024) An antibody that inhibits TGF- β 1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. *Science signaling*, 17(844), eadn6052.

Meadows AM, et al. (2023) N-arachidonylglycine is a caloric state-dependent circulating metabolite which regulates human CD4+T cell responsiveness. *iScience*, 26(5), 106578.

Lo TC, et al. (2023) Priming of macrophage by glycosphingolipids from extracellular vesicles facilitates immune tolerance for embryo-maternal crosstalk. *Developmental cell*, 58(22), 2447.

Schnizer C, et al. (2022) Persistent humoral and CD4+ TH cell immunity after mild SARS-CoV-2 infection-The CoNAN long-term study. *Frontiers in immunology*, 13, 1095129.

Pymm P, et al. (2022) Epitope length variants balance protective immune responses and viral escape in HIV-1 infection. *Cell reports*, 38(9), 110449.

Andreas N, et al. (2022) Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. *Vaccines*, 10(1).

Xiao C, et al. (2022) SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response. *iScience*, 25(3), 103934.

Pan Y, et al. (2021) The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF- κ B-mediated inflammation. *British journal of pharmacology*, 178(24), 4907.

Xiao C, et al. (2021) Optimization of antigen-specific CD8+ T cell activation conditions for infectious diseases including COVID-19. *STAR protocols*, 2(3), 100789.

Kaufmann M, et al. (2021) Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. *Med (New York, N.Y.)*, 2(3), 296.

Hu X, et al. (2021) M351-0056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA. *British journal of pharmacology*, 178(6), 1445.